Katrien De Vos appointed Country President for AstraZeneca Switzerland

Baar, 16 November 2020 – Effective 16th November 2020, Katrien De Vos has been appointed to the position of Country President for AstraZeneca Switzerland. She will succeed Andrea Mugan, who took on a new position as Global VP Oncology, Head of DDR (DNA Damage Response) Marketing at AstraZeneca.


Katrien De Vos holds a PhD in Applied Physics for personalised diagnostics, from Ghent University, as well as a professional certificate in Business Administration from the Vlerick Business School. She joined AstraZeneca in 2011 and until today held a number of key roles across the organisation, most recently as Global Head of COPD in the therapy area of Respiratory & Immunology, located in Washington DC, USA.

I am excited to join the Swiss organization and to further strengthen the position of AstraZeneca as one of the most exciting biopharmaceutical companies in Switzerland. In these unprecedented times I'll especially focus on AstraZeneca's highest priority to make our innovative medicines and the potential COVID-19 vaccine and treatments available to patients in Switzerland.

Katrien De Vos, Country President AstraZeneca Switzerland

Katrien De Vos succeeds Andrea Mugan. Under her leadership, AstraZeneca Switzerland received more than ten new product or indication approvals in therapy areas such as oncology, asthma, diabetes and heart failure. In addition, AstraZeneca was recognized as one of the best employers in Switzerland for the third year in a row, with a diverse team where more than 50% of management positions are held by women.

AstraZeneca’s focus on health and society

While the novel coronavirus continues to spread worldwide, the continued supply of our medicines to patients, and to safeguard the health and wellbeing of all our employees and communities, remains the top priority. AstraZeneca continues its efforts to develop treatments and preventative interventions, including its potential AZD1222 COVID-19 vaccine, and make them available broadly and equitably around the world.


AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca in Switzerland

AstraZeneca has 120 employees who are responsible for coordinating business operations in Switzerland. Our site in Baar is also the headquarters of the Europe & Canada Commercial Regional Team and the Europe & International Oncology Team, which employ a further 40 staff in Switzerland. Our primary therapeutic areas are Oncology, Cardiovascular, Renal and Metabolism, and Respiratory & Immunology. To meet our climate goals ahead of schedule, we are working tirelessly to further reduce CO2 emissions and waste. As part of our Ambition Zero Carbon strategy, we are transitioning to a carbon-free business operation by taking steps to reduce and ultimately eliminate greenhouse gas emissions. In 2020, AstraZeneca Switzerland was recognized by its employees for the third time as an outstanding employer, and was awarded the external “Great place to work®” certification.

Find out more: astrazeneca.ch

AstraZeneca Switzerland Media Department

Tel. +41 (0) 41 725 75 75; info@astrazeneca.ch

Dr. Angelika März, Corporate Affairs Lead

CH-3321, 11/2020

© 2020 AstraZeneca AG, Neuhofstrasse 34, 6340 Baar, Switzerland. All rights reserved.